|
Market Closed -
Nasdaq
16:00:00 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 28.10 USD | +4.69% |
|
+0.36% | +22.12% |
| 08-10 | Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 08-05 | Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis | MT |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| DMRA | Delayed | |
CBOE
| DMRA | Real-time |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bullish | Bullish |
| Resistance | 29.54 | 32.99 | 34.14 |
| Spread/Res. | -4.87% | -14.82% | -17.69% |
| Spread/Supp. | +8.54% | +8.54% | +151.79% |
| Support | 25.89 | 25.89 | 11.16 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- DMRA Stock
- Charts Damora Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
